

REMARKS/ARGUMENTS

The Applicant thanks the Examiner for the Office Action dated April 22, 2008.

Specification

The Abstract has been amended by way of replacing the term “comprising” with “including”. Further trivial amendments have been made to the specification to improve its clarity.

The term netpage is a generic term coined by the Applicant to describe the interactive page-based system described in detail in the specification. Since netpage is not a registered trade mark, it does require capitalization.

Double Patenting

A terminal disclaimer is filed herewith, which disclaims the term of any patent granted from the present application extending beyond the term US Patent Nos. 7,024,941 and 7,282,164.

Claim Rejections – 35 USC § 102

The subject-matter of claim 25 (in part) has been incorporated into claim 1.


The Applicant contests the Examiner’s assertion that claim 1 is anticipated by the disclosure of Albert. The relevant passage of Albert appears to be at column 3, lines 12-50. However, none of the substituents L¹-L⁴ in Albert’s generic formula (III) falls within the scope of claim 1. Albert merely discloses alkyl substituents, cycloalkyl substituents, ether substituents, phenyl substituents etc.

Accordingly, the Examiner is requested to reconsider the rejection under 35 USC 102.

It is respectfully submitted that all of the Examiner's objections have been successfully traversed. Accordingly, it is submitted that the application is now in condition for allowance. Reconsideration and allowance of the application is courteously solicited.

Very respectfully,

Applicant/s:




Lachlan Everett Hall



Alexandra Artemis Papadakis



Damon Donald Ridley




Scott Matthew Starling



Simone Charlotte Vonwiller



Kia Silverbrook



Paul Lapstun

C/o: Silverbrook Research Pty Ltd
393 Darling Street
Balmain NSW 2041, Australia

Email: kia.silverbrook@silverbrookresearch.com

Telephone: +612 9818 6633

Facsimile: +61 2 9555 7762